Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

An investigational once-weekly amylin receptor agonist conferred substantial weight loss across six different dosing regimens for adults with overweight or obesity, researchers reported in a phase 2 ...

We made several strategic additions during market weakness including Fast Retailing, Chipotle, Gartner and Adyen. Read more here.

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for ...

We sold Novo Nordisk out of the portfolio due to two concerns that made us question the company’s ability to deliver ...

Novo Nordisk (NYSE:NVO) shares have drawn attention recently as investors look for clues about what might be driving the stock's movement this month. In the absence of major headlines, valuation and ...